Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Merck KGaG Doesn’t Expect Erbitux Lung Tumor Approval, FTD Says

Feb. 14 (Bloomberg) -- - Merck KGaA says that its Erbitux drug has less than a 50 percent chance of being approved for lung tumor treatment, Financial Times Deutschland reported, citing a briefing for JPMorgan Chase & Co. analysts.

Erbitux is the company’s second biggest seller after its Rebif multiple-sclerosis treatment, according to the newspaper.

To contact the reporters on this story: Karin Matussek in Berlin at

To contact the editor responsible for this story: Anthony Aarons at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.